Vigilant Bioservices Open House In the UMB Biopark 801 W. Baltimore St., Suite 303, Baltimore, Md. 21201 (street parking & garage on same block west of Biopark)
Wednesday, November 16th
(Tours start on the half hour) 11am – 1pm 3pm – 5pm
Join us for the monthly Science in the City Happy Hour With the tenants of the Biopark 5:00pm-6:30pm
RSVP: tokeefe@vigilantbioservices.com
Stephen Quake’s laboratory at Stanford University looks like biology’s version of Thomas Edison’s famous New Jersey workshop. Roll-down curtains cast shadows across odd devices buzzing and clicking in the aisles. You half expect to find Quake, author of 135 patents and rarely seen wearing anything other than a faded polo shirt, sleeping on one of the benches, just as the Wizard of Menlo Park was known to.
The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC).
Immunomic Therapeutics is committed to providing a workplace that bolsters scientific ideas. The Cancer Discovery Incubator will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.
New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions have helped the city start to move forward. Another step in that direction was taken this morning, with the launch of what’s being called Bridge Medicines.
Reston-based telemedicine provider Avizia Inc. raised $6 million in Series A funding, amping up a fundraising round we reported earlier this year to a total of $17 million.
Biotech venture capital is supposed to be the highest-risk/highest-reward type of investment there is. But many biotech VCs are actually pretty conservative, hesitant to wager on edgy science that might take a decade to pay off.
Maryland Stem Cell Research Commission announced today the launch of Accelerating Cure, a new initiative to support regenerative medicine and cell therapy technologies moving from research to commercialization and finally to clinical trials. Accelerating Cure will fund close to $9 million with its five programs to address the different stages the technologies need to go through. The Commission also announced that Dr. Amritha Jaishankar joined the team as the Award Manager for the Maryland Stem Cell Research Fund.
Kevin Plank’s underdog story has become synonymous with Baltimore — the city his company Under Armour calls home.
Now his investment company, Plank Industries, is looking to rebuild an entire area of the city. Billions of dollars will be poured into Port Covington in one of the largest urban redevelopment projects in the country, which will include housing, retail and an entrepreneurial ecosystem.
Entrepreneur, the magazine that celebrates small business, recently released a list of what they consider to be the 360 best small businesses America has to offer. And wouldn’t you know — some of #dctech’s own were among the companies named.
The list is not meant to showcase only companies that are growing really fast (we see you, Inc.) — it’s more of a congratulations to companies “that keep all their parts growing in harmony.” As such, each company on the list has been evaluated according to the metrics of impact, innovation, growth and leadership.
